Market closedNon-fractional
AC Immune/ACIU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About AC Immune
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Ticker
ACIU
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Lausanne, Switzerland
Employees
147
Website
www.acimmune.com
AC Immune Metrics
BasicAdvanced
$367M
Market cap
-
P/E ratio
-$0.70
EPS
1.27
Beta
-
Dividend rate
Price and volume
Market cap
$367M
Beta
1.27
Financial strength
Current ratio
7.779
Quick ratio
7.502
Long term debt to equity
1.836
Total debt to equity
2.301
Interest coverage (TTM)
-488.01%
Management effectiveness
Return on assets (TTM)
-20.85%
Return on equity (TTM)
-36.68%
Valuation
Price to revenue (TTM)
20.628
Price to book
2.68
Price to tangible book (TTM)
4.11
Price to free cash flow (TTM)
-7.03
Growth
Revenue change (TTM)
276.14%
Earnings per share change (TTM)
-25.90%
3-year revenue growth (CAGR)
67.49%
3-year earnings per share growth (CAGR)
-14.53%
What the Analysts think about AC Immune
Analyst Ratings
Majority rating from 4 analysts.
AC Immune Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
CHF 0
-100.00%
Net income
-CHF 18M
278.72%
Profit margin
0.00%
-100.00%
AC Immune Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-CHF 0.20
-CHF 0.18
-CHF 0.05
-CHF 0.18
-
Expected
-CHF 0.19
CHF 0.03
-CHF 0.11
-CHF 0.14
CHF 0.40
Surprise
3.67%
-754.26%
-54.25%
32.92%
-
AC Immune News
AllArticlesVideos
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Seeking Alpha·7 hours ago
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease
GlobeNewsWire·2 days ago
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AC Immune stock?
AC Immune (ACIU) has a market cap of $367M as of July 27, 2024.
What is the P/E ratio for AC Immune stock?
The price to earnings (P/E) ratio for AC Immune (ACIU) stock is 0 as of July 27, 2024.
Does AC Immune stock pay dividends?
No, AC Immune (ACIU) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next AC Immune dividend payment date?
AC Immune (ACIU) stock does not pay dividends to its shareholders.
What is the beta indicator for AC Immune?
AC Immune (ACIU) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell AC Immune stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.